The treatment and management of myelodysplastic syndromes (MDS) remains a challenge due to the heterogeneity of the disease, and early diagnosis and intervention are important factors in MDS. Several experts agree that there is a need to develop more effective first-line therapies, and numerous clinical trials are exploring novel agents and combinations that may improve patient outcomes.

In this exclusive podcast, you will hear from Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, Daniel Starczynowski, PhD, Cincinnati Children’s Hospital, Cincinnati, OH, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and David Sallman, MD, Moffit Cancer Center, Tampa, FL, who share their thoughts on why there are fewer treatment options for MDS patients compared to other hematological malignancies, the promise of CAR-T therapy and CD47 antibodies in MDS treatment, and more.